Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.
Also called NCT04952766
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose other
- Phase
- Phase 4
- Enrolled
- 196 participants
- Sponsor
- Centre Hospitalier Régional d'Orléans
- Registry
-
NCT04952766
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT04952766. Allocation not applicable; no masking; primary purpose other. Start 2021-03-26 (actual); primary completion 2022-02-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
- Acronym
- EREVA
- Condition
- Kidney Transplant
- Condition
- Myeloma
- Condition
- Cancer
- Condition
- Hematologic Malignancy
- Condition
- Multiple Sclerosis
- Condition
- Hypergammaglobulinemia
- Condition
- Malignant Tumor
- Condition
- Hiv
- Condition
- Diabetes Type 2
- Intervention (Biological)
- Biological samples
- Lead sponsor
- Centre Hospitalier Régional d'Orléans
Record details
- Record id
cardio:ct-nct04952766- Content hash
674ab26743b3ccaae9013a212226c4e3b08b4ef95d1315d2509ffc18dbba0964